Bristol-myers Squibb Compnay

Carl Ouellet

Francis Beaulieu

B Narasimhulu Naidu

Yasutsugu Ueda

Michael A Walker

Jacques Banville

John D Matiskella

Margaret E Sorenson

Timothy P Connolly

Roger Remillard

Serge Plamondon

Mark D Wittman

Mark R Krystal

Upender Velaparthi

Kurt Zimmermann

Anne Marinier

Stephan Roy

Chen Li

Nicholas A Meanwell

Makonen Belema

Annapurna Pendri

Alain Martel

Van N Nguyen

Manoj Patel

Katharine A Grant-Young

Kevin M Peese

Yuping Qiu

Yunhui Zhang

Amy Mae Bunker

Xuejie Yang

Christopher Zusi

Jonathan R Weiss

Ting T Yin

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

Tyrosine kinase inhibitors

Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Benzimidazole C-2 heterocycles as kinase inhibitors

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

Compounds having the formula (I),and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R, R, and Rare hydrogen, halogen, alkyl, or perfluoroalkyl; Ris an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and Ris a substituent on A as defined in the specification.

Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same

Growing community of inventors

Boucherville, Canada

Carl Ouellet